Patents by Inventor Edwin John Weeber
Edwin John Weeber has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11793177Abstract: The present invention concerns non-human animals with cells having a genome that is lacking the entire E3 ubiquitin ligase (Ube3a) gene (including all isoforms and alternative promoters). These animals are useful for modeling Angelman Syndrome. The invention also includes methods for assessing the effect of an agent, such as potential therapeutics, on an animal model by exposing the animal or cells, tissues, or organs isolated therefrom, to an agent of interest.Type: GrantFiled: October 3, 2017Date of Patent: October 24, 2023Assignees: UNIVERSITY OF SOUTH FLORIDA, THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE TEXAS A&M UNIVERSITY SYSTEMInventors: Edwin John Weeber, David J. Segal, Henriette O'Geen, Benjamin Pyles, Scott V. Dindot
-
Publication number: 20230277684Abstract: Angelman Syndrome (AS) is a genetic disorder occurring in approximately one in every 15,000 births. It is characterized by severe mental retardation, seizures, difficulty speaking and ataxia. The gene responsible for AS was discovered to be UBE3A and encodes for E6-AP, a ubiquitin ligase. A unique feature of this gene is that it undergoes maternal imprinting in a neuron-specific manner. In the majority of AS cases, there is a mutation or deletion in the maternally inherited UBE3A gene, although other cases are the result of uniparental disomy or mismethylation of the maternal gene. While most human disorders characterized by severe mental retardation involve abnormalities in brain structure, no gross anatomical changes are associated with AS. We have generated a Ube3a protein with additional sequences that should allow the secretion from cells and uptake by neighboring neuronal cells. This would confer a functional E6-AP protein into the neurons and rescue disease pathology.Type: ApplicationFiled: December 23, 2022Publication date: September 7, 2023Inventors: Kevin Ron Nash, Edwin John Weeber, Jennifer Leigh Daily
-
Patent number: 11629127Abstract: Disclosed herein are compounds for activating the Reelin signaling system for the treatment of neurological disorders Further provided are compounds and methods for activating a lipoprotein receptor, such as ApoER2 or VLDLR.Type: GrantFiled: April 18, 2022Date of Patent: April 18, 2023Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Edwin John Weeber, Qingyou Li, Melinda Marie Peters, Hana Marie Soueidan
-
Patent number: 11534500Abstract: Angelman Syndrome (AS) is a genetic disorder occurring in approximately one in every 15,000 births. It is characterized by severe mental retardation, seizures, difficulty speaking and ataxia. The gene responsible for AS was discovered to be UBE3A and encodes for E6-AP, an ubiquitin ligase. A unique feature of this gene is that it undergoes maternal imprinting in a neuron-specific manner. In the majority of AS cases, there is a mutation or deletion in the maternally inherited UBE3A gene, although other cases are the result of uniparental disomy or mismethylation of the maternal gene. While most human disorders characterized by severe mental retardation involve abnormalities in brain structure, no gross anatomical changes are associated with AS. We have generated a Ube3a protein with additional sequences that should allow the secretion from cells and uptake by neighboring neuronal cells. This would confer a functional E6-AP protein into the neurons and rescue disease pathology.Type: GrantFiled: November 7, 2017Date of Patent: December 27, 2022Assignee: University of South FloridaInventors: Kevin Ron Nash, Edwin John Weeber, Jennifer Leigh Daily
-
Publication number: 20220324805Abstract: Disclosed herein are compounds for activating the Reelin signaling system for the treatment of neurological disorders Further provided are compounds and methods for activating a lipoprotein receptor, such as ApoER 2 or VLDLR.Type: ApplicationFiled: April 18, 2022Publication date: October 13, 2022Inventors: Edwin John Weeber, Qingyou Li, Melinda Marie Peters, Hana Marie Soueidan
-
Patent number: 11306059Abstract: Disclosed herein are compounds for activating the Reelin signaling system for the treatment of neurological disorders. Further provided are compounds and methods for activating a lipoprotein receptor, such as ApoER2 or VLDLR.Type: GrantFiled: October 25, 2018Date of Patent: April 19, 2022Assignee: University of South FloridaInventors: Edwin John Weeber, Qingyou Li, Melinda Marie Peters, Hana Marie Soueidan
-
Publication number: 20210208142Abstract: A method and kit for diagnosing Angelman Syndrome by detecting and analyzing ubiquitination of the UBE3A protein in cerebrospinal fluid is presented. CSF is collected from a patient and incubated with a substrate, such as S5a, and ubiquitin. Ubiquitination of the substrate by UBE3A is measured and compared to a control sample for biochemical diagnosis of Angelman Syndrome. A method of determining the efficacy of a treatment is also presented in which CSF is collected from the patient both prior to and after treatment and incubated with a substrate and ubiquitin. Ubiquitination of the substrate by UBE3A is measured and an increase in ubiquitination in the sample obtained after treatment as compared to the reference sample collected prior to treatment indicates efficacy of the treatment.Type: ApplicationFiled: February 19, 2021Publication date: July 8, 2021Inventors: Edwin John Weeber, Hayden Elyse Greene
-
Publication number: 20200347018Abstract: Disclosed herein are compounds for activating the Reelin signaling system for the treatment of neurological disorders. Further provided are compounds and methods for activating a lipoprotein receptor, such as ApoER2 or VLDLR.Type: ApplicationFiled: October 25, 2018Publication date: November 5, 2020Inventors: Edwin John WEEBER, Qingyou LI, Melinda Marie PETERS, Hana Marie SOUEIDAN
-
Publication number: 20200113955Abstract: A novel vector, composition and method of treating a neurological disorder characterized by deficient UBE3A is presented. The UBE3A gene, which encodes for E6-AP, a ubiquitin ligase, was found to be responsible for Angelman syndrome (AS). A unique feature of this gene is that it undergoes maternal imprinting in a neuron-specific manner. In the majority of AS cases, there is a mutation or deletion in the maternally inherited UBE3A gene, although other cases are the result of uniparental disomy or mismethylation of the maternal gene. A UBE3A protein construct was generated with additional sequences that allow the secretion from cells and uptake by neighboring neuronal cells. This UBE3A vector may be used in gene therapy to confer a functional E6-AP protein into the neurons and rescue disease pathology.Type: ApplicationFiled: December 17, 2019Publication date: April 16, 2020Applicant: University of South FloridaInventors: Kevin Ron Nash, Edwin John Weeber
-
Publication number: 20190208752Abstract: The present invention concerns non-human animals with cells having a genome that is lacking the entire E3 ubiquitin ligase (Ube3a) gene (including all isoforms and alternative promoters). These animals are useful for modeling Angelman Syndrome. The invention also includes methods for assessing the effect of an agent, such as potential therapeutics, on an animal model by exposing the animal or cells, tissues, or organs isolated therefrom, to an agent of interest.Type: ApplicationFiled: October 3, 2017Publication date: July 11, 2019Inventors: EDWIN JOHN WEEBER, DAVID J. SEGAL, HENRIETTE O'GEEN, BENJAMIN PYLES, SCOTT V. DINDOT
-
Publication number: 20180104358Abstract: Angelman Syndrome (AS) is a genetic disorder occurring in approximately one in every 15,000 births. It is characterized by severe mental retardation, seizures, difficulty speaking and ataxia. The gene responsible for AS was discovered to be UBE3A and encodes for E6-AP, an ubiquitin ligase. A unique feature of this gene is that it undergoes maternal imprinting in a neuron-specific manner. In the majority of AS cases, there is a mutation or deletion in the maternally inherited UBE3A gene, although other cases are the result of uniparental disomy or mismethylation of the maternal gene. While most human disorders characterized by severe mental retardation involve abnormalities in brain structure, no gross anatomical changes are associated with AS. We have generated a Ube3a protein with additional sequences that should allow the secretion from cells and uptake by neighboring neuronal cells. This would confer a functional E6-AP protein into the neurons and rescue disease pathology.Type: ApplicationFiled: November 7, 2017Publication date: April 19, 2018Applicant: University of South FloridaInventors: Kevin Ron Nash, Edwin John Weeber, Jennifer Leigh Daily
-
Patent number: 9795580Abstract: The invention concerns a method of treating Angelman Syndrome (AS) in a subject, comprising inducing ketosis in the subject by administering a therapeutically effective amount of a ketone ester, such as an R,S-1,3-butanediol acetoacetate ester, wherein administration of the ketone ester elevates the blood ketone level in the subject. Other aspects of the invention include a method of increasing cognitive function and/or motor function in a subject with AS; and a method of decreasing seizures and increasing the latency to seize in a subject with AS.Type: GrantFiled: May 24, 2016Date of Patent: October 24, 2017Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Edwin John Weeber, Stephanie Lynn Ciarlone, Dominic Paul D'Agostino
-
Publication number: 20170000754Abstract: The invention concerns a method of treating Angelman Syndrome (AS) in a subject, comprising inducing ketosis in the subject by administering a therapeutically effective amount of a ketone ester, such as an R,S-1,3-butanediol acetoacetate ester, wherein administration of the ketone ester elevates the blood ketone level in the subject. Other aspects of the invention include a method of increasing cognitive function and/or motor function in a subject with AS; and a method of decreasing seizures and increasing the latency to seize in a subject with AS.Type: ApplicationFiled: May 24, 2016Publication date: January 5, 2017Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: EDWIN JOHN WEEBER, STEPHANIE LYNN CIARLONE, DOMINIC PAUL D'AGOSTINO
-
Patent number: 9364456Abstract: The invention concerns a method of treating Angelman Syndrome (AS) in a subject, comprising inducing ketosis in the subject by administering a therapeutically effective amount of a ketone ester, such as an R,S-1,3-butanediol acetoacetate ester, wherein administration of the ketone ester elevates the blood ketone level in the subject. Other aspects of the invention include a method of increasing cognitive function and/or motor function in a subject with AS; and a method of decreasing seizures and increasing the latency to seize in a subject with AS.Type: GrantFiled: June 30, 2015Date of Patent: June 14, 2016Assignee: UNIVERSITY OF SOUTH FLORIDAInventors: Edwin John Weeber, Stephanie Lynn Ciarlone, Dominic Paul D'Agostino